| Osteoporosis |
NCT04940845: Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults |
|
|
| Recruiting | 1 | 174 | RoW | HS-20090-2, Prolia | Shanghai Hansoh Biomedical Co., Ltd | Postmenopausal Osteoporosis | 06/22 | 06/22 | | |
NCT04435158: A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients |
|
|
| Completed | 1 | 107 | RoW | SHR-1222, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Osteoporosis | 07/22 | 07/22 | | |
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women |
|
|
| Completed | 1 | 90 | RoW | AGA2118, Placebo | Angitia Biopharmaceuticals, Angitia Australia Pty Ltd | Osteoporosis | 01/24 | 01/24 | | |
| Completed | 1 | 208 | Europe, RoW | AVT03, AVT03 proposed Biosimilar to Denosumab, Denosumab, Xgeva | Alvotech Swiss AG | This is a Phase I Study Conducted in Healthy Volunteers | 04/24 | 04/24 | | |
NCT05930704: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women |
|
|
| Recruiting | 1 | 45 | RoW | SHR-2017 injection, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Osteoporosis | 04/25 | 04/25 | | |
